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Summary  21 
Introduction: Metal-on-Metal (MoM) total hip arthroplasty (THA) has been associated 22 
to wear and metal-ions release, controversially related to a variety of clinical 23 
complications. Little is known about the relevant design-dependent parameters involved 24 
in this process. The present study investigated the correlation between metal ion release 25 
in blood and revision rate as a function of: (i) specific MoM implant modular design 26 
parameters, (i.e. acetabular cup and femoral head diameters, taper adapter material and 27 
size, femoral neck material and modularity and stem size); (ii) MoM bilaterality. 28 
Methods: Co and Cr ions concentration levels in blood of 75 patients were 29 
retrospectively-evaluated with a mean follow-up of 4.8 years (range: 1.8–6.3). Patients 30 
were divided in a unilateral and a bilateral group. Statistical analysis was performed to 31 
find any significant difference related to acetabular cup diameter, femoral head 32 
diameter, taper adapter material/size, neck material/size and stem size.  33 
Results: The bilateral MoM group had 4-times higher metal ion levels in blood than the 34 
unilateral one (p=0.017 only Cr), related to a higher revision rate (30% vs 20%): 35 
differences were 10-times higher particularly with a 48 mm femoral head diameter 36 
(p=0.012) and a Ti-alloy neck (p=0.041). Within the monolateral group using a shorter 37 
taper adapter and a shorter neutrally-oriented neck demonstrated higher ion levels 38 
(p=0.038 only Cr and p=0.008 only Co, respectively).  39 
Conclusion: The aforementioned design-features and MoM bilaterality are important 40 
risk-factors for metal-ion release in modular MoM THA. 41 
Keywords: Modular hip prosthesis; Metal-on-Metal; Metal ion release; Cobalt; 42 
Chromium; Revision; Metallosis.  43 
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Introduction 44 
Total hip arthroplasty (THA) faced an innovation in the last two decades mainly related 45 
to the exploitation of modularity, potentially adapting to any peculiarity in patients’ 46 
anatomy, and the introduction of new metal-on-metal (MoM) bearing surfaces, aimed at 47 
minimizing wear debris formation compared to conventional metal-on-polyethylene 48 
(MoP) couplings (1,2). 49 
Recent clinical experience highlighted new potential issues related to the release of 50 
metallic ions and the formation of corrosion products leading to many complications. 51 
Adverse Local Tissue Reaction (ALTR), osteolysis and pseudotumour formation have 52 
often been reported as a consequence of metal-ion release in presence of large (diameter 53 
≥36mm) MoM THA for a variety of implant designs (3–8). However, it must be 54 
recognized that no clear cause-effect relation has ever been quantitatively demonstrated 55 
(5). Moreover, some authors put under discussion the utility of metal ion levels 56 
detection alone as a reliable predictor of periarticular tissue reaction even in 57 
symptomatic patients (9,10). Clinical evidence pushed several national and international 58 
bodies to draw precautionary recommendations on the management and monitoring of 59 
metal ions levels in THA, particularly when MoM surface-bearings are used (caution 60 
range 2–7 µg/l, critical threshold 20 µg/l for Co) (11,12). 61 
Despite controversial results not always leading to painful symptoms may suggest the 62 
involvement of specific biological factors (13,14) other never-investigated design-63 
dependent parameters (i.e. implant size and materials) are expected to play a significant 64 
role. 65 
The aim of the present retrospective comparative study is, therefore, to investigate the 66 
correlation between metal ions release in blood and (i) specific MoM implant modular 67 
design parameters, (i.e. acetabular cup and femoral head diameters, taper adapter 68 
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material and size, femoral neck material and modularity and stem size), and (ii) MoM 69 
bilaterality. 70 
 71 
Materials and Methods 72 
Patients cohort 73 
75 subjects (51 males, 24 females), implanted with at least one primary MoM THA 74 
between March 2008 and December 2011, have been retrospectively analyzed. All 75 
patients provided written signature on informed consent. Indication for surgery was 76 
justified by one of the following reasons: coxarthrosis, rheumatoid arthritis or avascular 77 
necrosis. Patients were divided in two groups. The first one received a unilateral MoM 78 
THA (monolateral group). The second one underwent a staged-bilateral MoM THA 79 
(bilateral group). All surgeries were performed via a posterolateral approach, the 80 
piriformis and conjoined tendons and the posterior capsule were repaired in separate 81 
layers using a transosseous technique. All patients involved in the study signed the 82 
informed consent for the treatment of their data. 83 
Implants 84 
All patients were implanted with at least one THA composed by a Harmony modular 85 
cementless femoral hip stem (Symbios Orthopédie SA, Yverdon-Les-Bains, 86 
Switzerland), a modular neck in Ti6Al4V or CoCrMo alloys coupled to a MaxiMoM 87 
taper adapter in CoCrMo or Ti6Al4V alloys, respectively, and a MaxiMoM femoral 88 
head-cup system (Symbios Orthopédie SA, Yverdon-Les-Bains, Switzerland) with a 89 
large diameter MoM CoCrMo couple bearing. 90 
The femoral stems ranged between 9 and 16 in size. The neck length was classified 91 
according to the manufacturer as short and long. The taper adapters were classified 92 
according to the manufacturer depending on their size small (S), medium (M), large (L) 93 
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and extra-large (XL). The femoral head and the monoblock cup diameters ranged in 94 
between 40 and 56mm and 48 to 64mm, respectively.  95 
Metal ion level-measurements 96 
Patients were retrospectively assessed for postoperative cobalt and chromium ions level 97 
in venous blood. All patients with a MoM implant underwent blood metal ion 98 
determination as part of a monitoring program at our institution. Recorded analyses 99 
were extracted directly from IRCCS Galeazzi Orthopaedic Institute database. 100 
Co and Cr ions concentration levels were expressed in µg/l. Data were organized for 101 
each of the two groups and within each group as a function of the design feature of 102 
interest, namely: acetabular cup diameter, femoral head diameter, taper adapter material 103 
and size, neck material and size, stem size. 104 
Clinical evaluation and Imaging 105 
Patients routinely received a radiograph (X-ray) to confirm a correct implant positioning 106 
and osseointegration. Each patient was periodically followed by an attending physician, 107 
who performed a physical evaluation of any symptoms (e.g. pain, functional 108 
impairment). Further metal-ion analysis in blood and/or diagnostic imaging analysis 109 
were requested in some cases. Extra-routine radiographic analysis was further requested 110 
to check for suspected images of osteolytic areas around the implant or loosening. 111 
According to international consensus (11,12), specific symptomatic patients underwent 112 
extra-routine nuclear Magnetic Resonance Imaging (MRI), using a Metal Artifact 113 
Reduction Sequence (MARS) protocol, to look for the presence of cystic/solid soft 114 
tissue masses.  115 
In specific cases, the attending physician decided for a revision surgery upon careful 116 
evaluation of all acquired information. 117 
Statistical analysis 118 
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Statistical analyses were carried out with IBM SPSS Statistics 24.0 (SPSS Inc., 119 
Chicago, Illinois). Preliminary multilinear regressions were undertaken to evaluate the 120 
relationship of Co and Cr ions levels to time and other specific design-features. A 121 
logarithm was necessary to transform the asymmetric metal ion distributions to 122 
approximately normal distributions (16, 17), as confirmed by Shapiro-Wilk normality 123 
test. Student’s t-test was used to compare unilateral and bilateral MoM patients’ groups 124 
and subgroups for metal levels assuming a significance level of 95% (p<0.05). Metal 125 
ion levels were presented as box-plot whenever possible (number of samples ≥3), 126 
specific values were reported otherwise. 127 
To keep consistency, only patients with complete metal ion levels data are discussed 128 
herein against X-rays and MRI imaging analysis. The revision rate was reported in 129 
terms of absolute (over the whole population) and relative (for each patients’ group) 130 
frequency. No attempt was made to quantitatively correlate metal ion levels with 131 
positive MRIs, X-rays nor symptoms. 132 
 133 
Results 134 
Patients cohort 135 
65 patients (86.7%) received a unilateral MoM THA (monolateral group) with a male-136 
female ratio of 42:23 (demographic data are summarized in Table 1). 2 patients within 137 
the monolateral group had a non-MoM THA with a monolithic femoral component on 138 
the contralateral side.  139 
10 patients (13.3%) received a staged-bilateral MoM THA (bilateral group) with a 140 
male:female ratio of 9:1. Only one patient had a Profemur Z femoral stem with modular 141 
neck, both in Ti6Al4V alloy, a CoCrMo taper adapter, a CoCrMo femoral head coupled 142 
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to a Procotyl acetabular (all components by Wright Medical Technology, Inc., 143 
Arlington, TN)  144 
Metal ion level-measurements 145 
Complete data were collected for 45 patients (60% of all patients) (Table 2): 38 in 146 
unilateral group (male:female ratio of 27:11), 7 in bilateral group (6:1). 19 patients 147 
(25.3%) presented incomplete or not-available data, while the remaining 11 (14.7%) 148 
were lost at follow-up. 149 
The metal ion level analysis was repeated over time for 15 patient; the average value 150 
was considered in the subsequent analysis since no correlation was observed over time. 151 
The linear regression analysis demonstrates a very weak correlation between metal ions 152 
concentrations and acetabular cup diameter, femoral head diameter and stem size for 153 
each patients’ group.  154 
In general, the bilateral MoM group (Co: 44.9±42.7µg/l; Cr: 23.0±21.4µg/l) exhibited 155 
4-fold higher metal ion levels in blood than the unilateral one (Co: 10.0±7.5µg/l; Cr: 156 
4.5±3.6µg/l), however they resulted significant only for Cr (p=0.017) (Table 2, Figure 157 
1). 158 
As regards intergroup comparison, we found significantly higher Cr levels in bilateral 159 
group than in unilateral one with a 48mm head diameter (respectively, 43.2±32.8µg/l 160 
vs. 2.3±0.8 µg/l, p=0.012; Figure 1), as well as with a Ti6Al4V neck material 161 
(respectively, 42.6±33.1µg/l vs. 3.5±2.2µg/l, p=0.041; Figure 3). Despite the trend is 162 
similar, no statistical difference was met for Co. 163 
About unilateral intragroup comparison, we found significantly higher Cr and Co levels, 164 
respectively, with a short (S) taper adapter size than a medium (M) (respectively, 165 
9.9±7.1µg/l vs. 2.4±1.2µg/l, p=0.038; Figure 2) and with a shorter neutrally-oriented 166 
neck size  instead of a longer (23.5±15.8 µg/l vs. 3.5±1.6 µg/l, p=0.008; Figure 3). 167 
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No further significant differences were detected within each group nor among them 168 
considering cup diameter, taper adapter material (Figure 2), nor stem size (Figure 4) 169 
within the monolateral group. 170 
Clinical evaluation and Imaging 171 
In 37/75 patients (49% of total population) a further radiographic analysis was requested 172 
(Table 1). Clear osteolytic areas and implant mobilization were positively assessed in 13 173 
of them (17% of all patients): incidence was 2-fold higher in the bilateral group 174 
compared to the monolateral one (respectively, 4/10 vs. 9/65). 175 
30 patients (40% of total population) underwent an MRI, eventually according to an 176 
enhanced MARS protocol (Table 1), confirming the presence of cystic/solid soft tissue 177 
masses in 23 cases (31% of all patients): again, the incidence was 2-times higher for the 178 
bilateral group compared to the monolateral (respectively, 5/10 vs. 18/65). 179 
When considering only patients with complete metal-ions level data, the relative 180 
incidence of positive RXs and MRIs confirmed to be about 2-times higher for the 181 
bilateral MoM group than the monolateral (Table 2).  182 
Revision 183 
16 patients (21% of total population) underwent revision surgery at an average 184 
postoperative time of 3.5±1.1 years (Tables 1,2). In all revised cases, a ceramic head 185 
(Biolox Delta) was coupled to highly-cross-linked-polyethylene (XLPE) upon revision. 186 
Revision surgery due to sepsis was performed in 2 patients following a two-stage 187 
procedure with an antibiotic-loaded spacer. 188 
The absolute revision rate was higher for the bilateral group (30%), but the sample size 189 
was different (13/65 vs. 3/10, respectively). All revised patients reported symptoms (i.e. 190 
pain, functional impairment), sometimes confirmed through X-rays or MRI imaging 191 
analysis (Supplementary Material 1,2).  192 
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Considering only patients with complete metal-ions level data (Table 2), the relative 193 
frequency of revision was slightly lower (16%), but similar for both groups (bilateral: 194 
2/7 vs. monolateral: 5/38). 195 
In general, all revised patients (Co: 54.3±45.2 µg/l; Cr: 30.0±23.0 µg/l) demonstrated 196 
significantly higher (Co: p=0.014, Cr: p=0.011) metal ion levels in blood than those 197 
unrevised (Co: 15.2±18.0 µg/l; Cr: 7.4±9.2 µg/l) (Table 2). It is important to notice that 198 
such a result was not confirmed by a statistical difference between revised and 199 
unrevised patients within the monolateral group (Co: p=0.104, Cr: p=0.060). 200 
Among the 7 revised patients with complete metal-ion level data (Supplementary 201 
Material 2), 5 had a positive MRI: 2 patients overcame the threshold of 20 µg/l for Co, 202 
while 2 were beyond the caution range for Co (2–7 µg/l). Despite the 2 remaining 203 
patients were in the caution range, both of them were revised due to implant loosening, 204 
but in one case a prosthetic joint infection (PJI) was the leading cause. 205 
 206 
Discussion  207 
In the present study, we considered a large-head MoM THA design (femoral head 208 
diameters: 40–56 mm), based on  modular parts differing in size and material, which has 209 
never been considered in the previous literature. Even considering only the unilateral 210 
group (the only with enough samples), we noticed a slight trend toward higher average 211 
metal ion levels and higher absolute number of revisions with lower femoral head 212 
diameters (Figure 1): 8 cases of revision at 44 mm, 3 at 40 mm and only 2 at 48 mm. 213 
Being femoral head diameter and acetabular cup size roughly proportional, the same 214 
trend could be discussed also for the latter parameter. Neglecting isolated peak values, 215 
the highest average metal ions concentrations were met at 44 mm for each of the two 216 
groups, without any significant difference compared to other diameters. A large 217 
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systematic review reported highest metal ion concentrations after treatment with 218 
stemmed large-head MoM-implants and hip resurfacing arthroplasty(5), particularly in 219 
female gender (15). Beaulé and colleagues demonstrated that large-head MoM THA had 220 
significantly-higher Co level at 6-month, not confirmed for Cr, compared to hip-221 
resurfacing system (16).  222 
A pattern similar to the one we reported, with trend for ions concentration decreasing as 223 
bearing diameter increased, has been already showed for large-diameters THA (>55 224 
mm) and hip resurfacing systems (17). Conversely, significantly higher Co levels for 225 
larger-head diameters (≥50 mm) compared to relatively-smaller head (range: 42–48 226 
mm) in modular THA were also reported (8). The explanation for higher metal ion 227 
release in smaller diameters should be searched in the reduced arcs of cover and the 228 
predisposition to edge wear of these components. On the other hand the open design of 229 
larger femoral heads (≥50 mm) with a larger contact surface for metal corrosion can 230 
account for higher metal ion levels compared to the closed head designs (≤48 mm). 231 
Despite the debate is still open, international consensus-based statements on ions levels 232 
in blood have been defined: the threshold value for clinical concern is expected to be 233 
within the range of 2–7 µg/l, whereas excessive elevation (Co approximately 20g/L 234 
or above) of metal ions should prompt discussion with the patient about revision surgery 235 
because of potential osteolysis, tissue necrosis, and long-term health effects (11,12). 236 
Moreover, the current recommendation is to support metal ion level evaluation with 237 
specific imaging techniques (e.g. ultrasound, MARS-MRI, CT Scan,) and a systematic 238 
follow-up on patients implanted with a MoM bearing . 239 
Beside femoral head diameters, other design-parameters needs further discussion 240 
against metal ion release. In fact, modular MoM THA designs often have several 241 
interfaces undergoing micromotions and susceptible of wear debris formation. 242 
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Vendittoli demonstrated that the addition of a taper adapter with modular junctions and 243 
an open femoral head design causes more Co release than bearing surface wear in 244 
modular large-head MoM THA (8). Moreover, little is known on the consequences of 245 
using modular femoral necks and taper adapter with a variety of sizes and/or materials. 246 
To the best of our knowledge, these aspects received very little attention in the 247 
literature. 248 
As for implant modularity, the data collected for the unilateral group demonstrated 249 
significantly higher Cr levels using a shorter taper adapter size, while we noticed only a 250 
trend towards increased metal ion release with a Ti6Al4V taper adapter: in both cases 251 
this result is associated to a higher revision rate (Figure 2). Despite only Co levels are 252 
significantly higher using a smaller neck instead of a long one (Figure 3), we noticed a 253 
trend towards a slightly higher revision rate (7/65 vs. 6/65, respectively); even though 254 
the average ion levels are similar, a femoral neck in CoCr is however related to a higher 255 
number of revision compared to Ti6Al4V (Figure 3). These results may suggest that the 256 
modularity of neck- taper adapter system play an important role. In particular, 257 
increasing the bending stiffness of the neck-taper system (i.e. shorter/stiffer CoCr neck 258 
+ shorter adapter size), may promote wear on the taper adapter, which would work as a 259 
damper interposed in-between the neck and the head taper joint. This mechanism may 260 
be promoted especially with a softer Ti6Al4V taper adapter with a reduced thickness 261 
(i.e. small size). To the best of our knowledge, only one recent radiographic study 262 
seemed to confirm our results towards an increased risk of complication (i.e. 263 
pseudotumour formation) in the long-term when a titanium taper adapter is used (18).  264 
As concern MoM bilaterality, we found that, in general, having a bilateral MoM THA 265 
led to higher Co and Cr values compared to the unilateral group, but they were 266 
significant only for Cr. Interestingly, Witzleb reported the same results for a THA with 267 
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a smaller (28 mm) diameter until 1 year, but thereafter they did not notice any 268 
difference (19). Pelt found slightly higher cobalt levels in well-functioning MOM THA, 269 
not in chromium (20), while other study did not notice any difference (21). However, 270 
the difference we observed in metal-ions level found a confirmation in the absolute 271 
revision rate, which was higher for the bilateral group (3/10 or 30%) compared to the 272 
monolateral one (13/65 or 20%). Other studies including a variety of modular MoM 273 
THA designs reported variable revision rates: Bernthal found a 17% (or 12/70) for ultra-274 
large-diameter femoral heads paired with a monoblock acetabular cup (22), while 275 
Mauer-Ertl reported a 27% (or 12/44) for large-head articular surface replacement 276 
systems (44-58mm) (23); Langton obtained a 6% (or 5/87) (24) and a 49% (or 42/87) 277 
(17) for large-head diameters THA (39-57mm and >55mm, respectively), whilst 278 
Koziara reported a 22% (or 21/66) (25).  279 
The current retrospective study presents some intrinsic limitations. Information about 280 
the preoperative ion-concentration levels is missing. Data were not acquired at regular 281 
follow-up times, nor they were homogeneously distributed across the two groups. The 282 
limited sample size made, sometimes, impossible to perform any quantitative statistical 283 
analysis. This aspect was more critical for the bilateral MoM group, where different 284 
implant size and material were mixing up adding a confounding effect. Moreover, issues 285 
related to the ion level evaluation (9,10), resulted in very highly-dispersed data, with 286 
rather high and isolated values.  287 
The paper related modular design features of MoM THA to significant differences in Co 288 
and Cr levels in blood: neck length and taper adapter size were found to contribute in 289 
increasing metal-ion release. 290 
Having a bilateral MoM THA may lead to higher absolute metal-ion levels in blood 291 
compared to a unilateral implant, however the revision rate is comparable. 292 
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Complete diagnostic imaging analysis and a rigorous clinical evaluation of patients, 293 
represent necessary information to integrate metal ion level measurements and to 294 
support physicians in decision-making process. 295 
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Figure 1: Box-plot of metal ions concentration levels and revision rate (calculated over the whole patients’ population) for monolateral and 
bilateral MoM groups.  
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Figure 2: Box-plot of metal ions concentration levels and revision rate (calculated over the whole patients’ population) as a function of taper 
adapter material. Statistically significant differences are indicated (*: p<0.05). 
  385 
18 
 
 
 
 
 
Figure 3: Box-plot of metal ions concentration levels and revision rate (calculated over the whole patients’ population) as a function of femoral 
neck material. Statistically significant differences are indicated (* or °: p<0.05). 
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Figure 4: Box-plot of metal ions concentration levels and revision rate (calculated over the whole patients’ population) as a function of stem size.  
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Table 1: General demographic information for each patients’ group and the overall population. 
 Monolateral group Bilateral MoM group All patients 
Patients’ population (#) 65 (42:23) 10 (9:1) 75 (51:24) 
Age at first surgery (years) 
mean ± standard dev. (min – max) 
58.2 ± 11.1 (22.2 – 75.7) 56.2 ± 9.7 (38.6 – 72.7) 57.9 ± 10.9 (22.0 – 75.7) 
Age at second surgery (years) - 
0.8 ± 0.8 
(0.0 – 2.6) 
- 
Lost patients at follow-up (#) 11 0 11 
(%) 16.9% - 14.7% 
Patients with incomplete or not available data (#) 16 3 19 
(%) 24.6% 30.0% 25.3% 
Number of patients with complete ions level data (male:female) 38 (27:11) 7 (6:1) 45 (33:12) 
(% of total population) (male : female) 58.5% (64.3 : 47.8) 70.0% (66.7 : 100) 60.0% (64.7 : 50.0) 
Follow-up time (years) 4.0 ± 0.4 (3.1 – 6.4) 4.1 ± 0.5 (2.7 – 6.0) 4.0 ± 0.4 (2.7 – 6.4) 
Patients with extra-routine RX analysis (#) 29 8 37 
(% of total population) 44.6% 80.0% 49.3% 
Positive extra-routine RX analysis (#) 9 5 14 
(% of total population) 13.8% 50.0% 18.7% 
Patients with extra-routine MRI (conventional / MARS) analysis (#) 23 (7 / 16) 7 (3 / 4) 30 (10 / 20) 
(% of total population) 35.4% (10.8 / 24.6) 70% (30 / 40) 40% (13.3 / 26.7) 
Patients with positive extra-routine MRI (conventional / MARS) analysis (#) 18 (6 / 12) 5 (2 / 3) 23 (8 / 15) 
(% of total population) 27.7% (9.2 / 18.5) 50% (20 / 30) 30.7% (10.7 / 20.0) 
Number of revised patients (#) (male:female) 13 (7:6) 3 (2:1) 16 (9:7) 
(%) (male : female) 20.0% (16.7 : 6.1) 30.0% (22.2 : 100) 21.3% (17.7 : 29.2) 
Age at revision (years) (male:female) 3.4 ± 1.1 (1.7 – 4.8) 5.0 ± 2.1 (2.8 – 7.0) 3.7 ± 1.4 (1.7 – 7.0) 
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Table 2: Demographic information for patients with complete metal-ions level data.  
*: Significant difference compared to the monolateral group (p<0.05). 
 Monolateral group Bilateral MoM group All patients 
Patients with complete Co-level data (#) 38 (27:11) 7 (6:1) 45 (33:12) 
(% of total population) 58.5% (64.3 : 47.8) 70% (66.7 : 100) 60% (64.7 : 50) 
Follow-up time (years) 4.0 ± 0.4 (3.1 – 6.4) 4.1 ± 0.5 (2.7 – 6.0) 4.0 ± 0.4 (2.7 – 6.4) 
Co ion level (µg/l) 10.0 ± 7.5 (0.3 – 80.1) 44.9 ± 42.7 (2.5 – 234.8) 15.2 ± 18.0 (0.3 – 234.8) 
Cr ion level (µg/l) 4.5 ± 3.6 (0.1 – 40.8)   23.0 ± 21.4 (1.7 – 119.0) * 7.4 ± 9.2 (0.1– 119.0) 
Patients with Co < 2 µg/l (#) 9 0 9 
(% of patients with complete ion level data) 23.7% - % 20% 
Patients with Co in the range 2–7 µg/l (#) 12 4 16 
(% of patients with complete ion level data) 31.6% 57.1% 35.6% 
Patients with Co in the range 7–20 µg/l (#) 16 1 17 
(% of patients with complete ion level data) 42.1% 14.3% 37.8% 
Patients with Co >20 µg/l (#) 3 2 5 
(% of patients with complete ion level data) 7.9% 28.6% 11.1% 
Patients with extra-routine RX analysis (#) 17 6 23 
(% of patients with complete ion level data) 44.7% 85.7% 51.1% 
Patients with positive extra-routine RX analysis (#) 5 2 7 
(% of patients with complete ion level data) 13.1% 28.6% 15.6% 
Patients with extra-routine MRI (conventional / MARS) analysis (#) 17 (5 / 12) 5 (2 / 3) 22 (7 / 15) 
(% of patients with complete ion level data) 44.7% (13.1 / 31.6) 71.4% (28.6 / 42.9) 48.9% (15.6 / 33.3) 
Patients with positive extra-routine MRI (conventional / MARS) analysis (#) 12 (4 / 8) 4 (1 / 3) 16 (5 / 11) 
(% of patients with complete ion level data) 31.6% (10.5 / 21.1) 57.1% (14.3 / 42.9) 35.6% (11.1 / 24.4) 
Number of revised patients (#) 5 (3:2) 2 (1:1) 7 (4:3) 
(% of patients with complete ion level data) (male : female) 13.2% (11.1 : 18.2) 28.6% (16.7 : 100) 15.6% (12.1 : 25.0) 
(% of total population) (male : female) 7.8% (7.1 : 8.7) 20% (10.0 : 10.0 ) 9.3% (7.8 : 12.5) 
Follow-up time (years) 3.5 ± 0.2 (3.1– 4.2) 3.9 ± 0.8 (3.3 – 4.5) 3.6 ± 0.3 (3.1 – 4.5) 
Co ion level (µg/l) 18.2 ± 10.4 (3.8 – 54.7) 155 ± 148 (49 – 260) 54.3 ± 45.2 (3.8 – 260) 
Cr ion level (µg/l) 12.2 ± 8.3 (1.3 – 40.8) 69.6 ± 69.9 (20.1 – 119) 30.0 ± 23.0 (1.3 – 119.0)  
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Supplementary Material 1: Diagnostic information for revised patients with 
incomplete/not available metal-ions level data and diagnostic imaging information 
(n.a.: not available; x: positive; o: negative; -: not done). 
Patient 
Co level 
(µg/l) 
Cr level 
(µg/l) 
RX RMI 
Symptoms 
(pain, functional 
impairment) 
Suggested 
Diagnosis 
M-20 100 n.a. o x x Metallosis 
M-19 10.3 1.3 o x x Metallosis 
M-21 x x x x x Metallosis 
M-3 x x x o x Cup mobilization 
M-26 n.a. n.a. x x n.a. Metallosis 
M-23 n.a. n.a. x x x Metallosis 
M-25 n.a. n.a. x - x 
Sepsis 
(Stapph.Epiderm.) 
M-24 n.a. n.a. x - x Cup mobilization 
M-22 o o o - x Stem mobilization 
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Supplementary Material 2: Diagnostic information for revised patients with complete 
metal-ions level data and diagnostic imaging information (x: positive; o: negative; -: 
not done). 
Patient 
Co level 
(µg/l) 
Cr level 
(µg/l) 
RX RMI 
Symptoms 
(pain, functional 
impairment) 
Suggested 
Diagnosis 
B-8 234.8 119.0 o x x Metallosis 
M-16 54.7 40.8 - x x Metallosis 
B-5 49.9 20.1 x - x Stem mobilization 
M-18 14.7 12.0 o x x Stem mobilization 
M-36 12.2 1.8 - x x Periarticular cysts 
M-17 5.8 5.1 x x x Stem mobilization 
M-12 3.8 1.3 x - x 
Sepsis, stem/cup 
loosening 
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